XM无法为美国居民提供服务。
A
A

Amgen

交易方向

交易者偏好

技术摘要

每小时

市场新闻

Viridian Therapeutics rises after upsized $225 mln stock offering

BUZZ-Viridian Therapeutics rises after upsized $225 mln stock offering ** Viridian Therapeutics VRDN.O shares up 1.1% at $20.02 after co's equity haul exceeds expectations ** Co late Weds announced pricing ~10.7 mln shares at $18.75 and preferred stock convertible into ~1.3 mln shares for $225 mln gross proceeds ** Deal size increased from planned $150 mln raise ** VRDN shares on Tues popped ~32% after co's drug, veligrotug, significantly reduced thyroid eye disease (TED) symptoms in late-stage
A

Weight-loss market to see 16 new drugs by 2029, report estimates

Weight-loss market to see 16 new drugs by 2029, report estimates Sept 10 (Reuters) - The market for weight-loss treatments is expected to see 16 new drugs vying for a slice of the lucrative business currently dominated by Novo Nordisk NOVOb.CO and Eli Lilly LLY.N , according to estimates from analysts at Morningstar and Pitchbook. In a joint report published on Monday, analysts estimated the market for obesity treatments could expand to $200 billion by 2031. The 16 drugs could launch by 2029, wi
A
P
R

UnitedHealth to remove AbbVie's Humira from some US drug reimbursement lists next year

UnitedHealth to remove AbbVie's Humira from some US drug reimbursement lists next year By Patrick Wingrove Sept 10 (Reuters) - UnitedHealth Group UNH.N said on Tuesday it will remove AbbVie’s ABBV.N blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement as of Jan. 1, 2025, and recommend less expensive biosimilar versions of the medicine instead.
A
C
P
T

Viridian's drug cuts thyroid eye disease symptoms in late-stage study

UPDATE 3-Viridian's drug cuts thyroid eye disease symptoms in late-stage study Shares rise 14% as drug meets main and secondary goals Analysts highlight less frequent dosing as a key advantage Jefferies estimates potential peak sales of $2 billion Adds analyst comment in paragraphs 3-5 and paragraph 9, background on disease throughout By Mariam Sunny Sept 10 (Reuters) - Viridian Therapeutics VRDN.O said on Tuesday its experimental treatment helped significantly reduce symptoms of thyroid eye dis
A

Amgen Presents New Data For First-In-Class IMDELLTRA (tarlatamab-dlle) In Small Cell Lung Cancer At WCLC 2024

BRIEF-Amgen Presents New Data For First-In-Class IMDELLTRA (tarlatamab-dlle) In Small Cell Lung Cancer At WCLC 2024 Sept 9 (Reuters) - Amgen Inc AMGN.O : AMGEN PRESENTS NEW DATA FOR FIRST-IN-CLASS IMDELLTRA™ (TARLATAMAB-DLLE) IN SMALL CELL LUNG CANCER AT WCLC 2024 AMGEN INC - DELLPHI-301 LONG-TERM FOLLOW-UP DATA DEMONSTRATE SUSTAINED SAFETY AND E
A

商品详情

热门商品

免责声明: XM Group仅提供在线交易平台的执行服务和访问权限,并允许个人查看和/或使用网站或网站所提供的内容,但无意进行任何更改或扩展,也不会更改或扩展其服务和访问权限。所有访问和使用权限,将受下列条款与条例约束:(i) 条款与条例;(ii) 风险提示;以及(iii) 完整免责声明。请注意,网站所提供的所有讯息,仅限一般资讯用途。此外,XM所有在线交易平台的内容并不构成,也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。

所有在线交易平台所发布的资料,仅适用于教育/资讯类用途,不包含也不应被视为用于金融、投资税或交易相关咨询和建议,或是交易价格纪录,或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。

本网站上由XM和第三方供应商所提供的所有内容,包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接,皆保持不变,并作为一般市场评论所提供,而非投资性建议。所有在线交易平台所发布的资料,仅适用于教育/资讯类用途,不包含也不应被视为适用于金融、投资税或交易相关咨询和建议,或是交易价格纪录,或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解,XM非独立投资研究提示和风险提示相关资讯,更多详情请点击 这里

风险提示: 您的资金存在风险。杠杆商品并不适合所有客户。请详细阅读我们的风险声明